Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions.

Authors: Joshua D. Brown
Journal of Clinical Medicine, 28 February 2020

Tetrahydrocannabinol (THC) is the primary psychoactive ingredient in cannabis. While the safety of THC and cannabis has been extrapolated from millennia of recreational use, medical marijuana programs have increased exposure among medically complex individuals with comorbid co…

Vaping Risks & Product Safety

Dr. Jahan Marcu gives research-based evidence on vape pen use and the EVALI situation, separating fact from conjecture on the vape pen crisis.

Value Of Cannabis Based Medicine (podcast)

Dr. Sherry Yafai is an ER doctor who also integrates cannabis-based medicine in her clinical practice at The Releaf Institute. In this interview with Joe Lemon, she explores the reasons why cannabis- informed healthcare providers are needed more and more.

Cannabis For Senior Mental Health

Dr. Phillip Grob, a geriatric psychiatrist, discusses the potential applications of cannabis for dementia and mental health challenges in the senior population.

Opiates & Cannabis: Current Perspectives & Case Studies

Dr. Sherry Yafai of the Releaf Institute discusses the applications of cannabis to reduce or replace the use of opiate drugs. She outlines the opioid epidemic and how cannabis may be used as a tool for harm reduction. 

The Use of Medical Cannabis For Dementia

Dr. Jefferey Hergenrather discusses the potential applications of cannabis for Alzheimer’s disease and dementia. He defines the specific mechanisms at play and how cannabis may be of benefit. 

The Antitumor Properties of Cannabis: Preclinical Evidence

Dr. Cristina Sanchez, a biochemist with over 20 years of experience as a cannabinoid researcher, outlines the preclinical evidence of cannabinoids on different types of cancer. 

Laboratory of Cancer Biology and Cannabinoid Research

Cannabis in Pediatric Practice

Novel Research on THCA